1. The Notified Body has just removed the CE mark from the only ONS device previously approved for rCM patients [6] . Therefore, any speculation on the definition of rCM criteria useful for ONS selection [4, 7] falls exclusively on future randomized controlled trials (RCTs). 2. The semantic debate on EHF criteria "requiring at least 3 different drugs from the following classes" [4] is a misinterpretation of our words: "at least 3 drugs from the following classes" (clearly shown on Table  two in our publication) contains 5 classes, 4 of which do not reach 3 items [1] . This fact clearly shows the inconsistency of this criticism. Furthermore, the observation on the minimum dose of prophylactic drugs used is not at all useful in a contest of a definition of refractoriness. 3. The EHF proposed criteria for rCM are defined "inconsistent with respect to MO, since criterion A requires no MO, but recommendations for detoxification are given in the notes". We think that the wide acceptance of any kind of detoxification procedure guarantees ICHD-3 beta CM diagnosis an uncomplicated purity from acute drugs abuse that might be a confusing factor in the given criteria. 4. The criticism about "laboratory and CSF analyses within the normal range, including CSF pressure", as reported in the notes at Table two of the EHF Statement, should be seen as a wide evaluation opportunity of many forms of secondary headaches without decontextualize the phrase deleting the term "laboratory".
We thank the authors of the letter for taking the time to comment our paper, yet this falls partially into our purposes to initiate a European and worldwide discussion on the refractoriness of primary headache disorders, coagulating the various emerging attempts [8] .
